FDA changes prescribing information for new Alzheimer's drug

Following weeks of criticism of the FDA decision to approve Biogen's Alzheimer's drug Aduhelm, experts within the health authority are narrowing the range of patients that the medicine is recommended for.
Photo: BRIAN SNYDER/REUTERS / X90051
Photo: BRIAN SNYDER/REUTERS / X90051
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Just one month after the US Food and Drug Administration (FDA) vouched for Biogen's drug Aduhelm for treating Alzheimer's disease, the authority has adjusted the prescribing information for this medication, which changes the patients that the drug should be recommended to.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading